Canada and Israel-based biopharma company NurExone Biologic Inc. (OTCQB:NRXBF) on Wednesday said its wholly owned U.S. subsidiary, Exo-Top Inc., entered into a binding memorandum of understanding with ExoLyra LLC outlining terms for a proposed exclusive distribution agreement in Mexico for Exo-Top’s naïve mesenchymal stem cell (MSC)-derived exosome products.
The companies intend to finalize a definitive agreement within 45 calendar days.
If completed, the arrangement would mark Exo-Top’s first structured commercial entry for its naïve MSC-derived exosome portfolio.